TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* postmenopausal women with age between 40-60 years~* Women complain about her sexual problem and her score of Female Sexual Function Index ≤ 26.5~Exclusion Criteria:~* women with previous use of hormonal replacement or anti-psychiatric drugs within 3 months~* women with history of or present premalignancies/malignancies~* women present with liver disease or abnormal liver enzyme~* women with active cardiovascular, cerebrovascular or thromboembolic disorders~* women with Present psychiatric disease~* Partner have sexual dysfunction

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Testosterone undecanoate (Type: EXPERIMENTAL): testosterone undecanoate 40 mg orally twice a week plus progynova 1mg oral daily
- placebo (Type: PLACEBO_COMPARATOR): placebo twice a week with progynova 1 mg oral daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of perennial allergic rhinitis.~* Age \>= 6 years old and \<= 12 years old.~* Patients in good general conditions, without any other relevant clinical condition except for perennial allergic rhinitis.~* Symptoms total score at admission \>= 8 (out of 15 possible). Individual symptoms (score 0 to 3 points) were: Sneezing or nasal pruritus, eye reddening or pruritus, nasal congestion, wet nose or with secretion (sniffing), secretion sensation at pharynx (post-nasal dripping).~* Number of symptoms: At least three.~Exclusion Criteria:~* Age \< 6 years old or \> 12 years old.~* Co-existence of acute sinusitis or some chronic condition different from asthma or atopic dermatitis.~* Presence of systemic fungal infections.~* Conscience or behavioral disturbances.~* Current oral or parenteral steroid treatment.~* Concomitant use of Phenobarbital, rifampicin, diphenylhydantoin or ephedrine.~* Known hypersensitivity to any of the study pharmacological combination components.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- loratadine/betamethasone oral solution (Type: EXPERIMENTAL): loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Body mass index (BMI) between 18.0 and 40.0~2. Stable (\>4 weeks prior to the Screening Visit) dose of statin therapy with or without ezetimibe~3. Fasting low-density lipoprotein cholesterol (LDL-C): ≥100 mg/dL for those without cardiovascular disease, or ≥70 mg/dL for those with cardiovascular disease.~4. Fasting triglycerides (TGs) \<400 mg/dL~Key Exclusion Criteria:~1. Women who are pregnant, nursing or breast feeding~2. Currently prescribed a lipid lowering agent other than a statin or ezetimibe.~3. Clinically significant disorder or laboratory abnormality that could contraindicate the administration of study drug, affect compliance, interfere with study evaluations, or confound the interpretation of study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CIVI 007, Dose A (Type: EXPERIMENTAL): Subcutaneous (SC) injection of a PCSK9 inhibitor- low dose given twice
- CIVI 007, Dose B (Type: EXPERIMENTAL): SC injection of PCSK9 inhibitor- dose titration
- CIVI 007, Dose C (Type: EXPERIMENTAL): SC injection of PCSK9 inhibitor- high dose given twice
- Placebo (Type: PLACEBO_COMPARATOR): Placebo SC injection matching PCSK9 inhibitor given twice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female patients~* Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray) fulfilling the Modified New York criteria for AS (1984)~* Patients should have been on NSAIDs with an inadequate response~* Patients who were regularly taking NSAIDs as part of their AS therapy are required to be on a stable dose~* Patients who had been on an anti-TNFα agent (not more than one) must have experienced an inadequate response~Exclusion Criteria:~* Chest X-ray (or MRI) with evidence of ongoing infectious or malignant process~* Patients with total ankylosis of the spine~* Patients previously treated with any biological immunomodulating agents except for those targeting TNFα~* Previous treatment with any cell-depleting therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 75 mg (Type: EXPERIMENTAL): Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks.
- Secukinumab 150 mg (Type: EXPERIMENTAL): Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male and female~* 18 - 64 years~* written informed consent~* physical exam: no abnormal findings unless considered irrelevant by the investigator~* uneventful medical history~* females: adequate contraception~Exclusion Criteria:~* pregnancy~* positive virology markers at first screening~* signs and symptoms of relevant autoimmunity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Dose Group 1 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
- Dose Group 2 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
- Dose Group 3 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
- Dose Group 0 (Type: PLACEBO_COMPARATOR): Control: Al(OH)3 Adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* postoperative UICC stage Ib/II gastric carcinoma~* indication for oral chemotherapy with doxifluridine~* ECOG performance status 0 or 1~* normal liver and kidney function~Exclusion Criteria:~* inability to answer the QoL scales~* concomitant therapy with steroids or biological response modifiers~* individual hypersensitivity to mistletoe preparations~* pregnancy or lactating~* participation in another clinical trial

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- doxifluridine (Type: ACTIVE_COMPARATOR): oral chemotherapy with the 5-FU prodrug doxifluridine
- doxifluridine + mistletoe extract (Type: EXPERIMENTAL): oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women aged at least 50 years~* A previous clinical diagnosis of osteoporosis~* At high risk for fracture~* Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na~Exclusion Criteria:~* History of metabolic bone disease other than osteoporosis~* History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of plaque-type psoriasis (with or without \[Psoriatic Arthritis\]PsA) for at least 6 months before the first administration of study drug~* A woman of childbearing potential must have a negative urine pregnancy test at screening and at Week 0 and agree to urine pregnancy testing before receiving injections~* Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug~* Agree not to receive a Bacille Calmette-Guérin (BCG) vaccination during the study, or within 12 months after the last administration of study drug~* Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during study~Exclusion Criteria:~* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances~* Has previously received guselkumab or secukinumab~* Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers~* Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance; or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly~* Is unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I: Guselkumab Plus Placebo (Type: EXPERIMENTAL): Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
- Group II: Secukinumab (Type: ACTIVE_COMPARATOR): Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females, age ≥18 years~2. Exclusive CCR5-tropic virus at Screening Visit as determined by Trofile™ DNA Assay~3. On stable antiretroviral therapy for last 12 months~4. Subject has two or more potential alternative antiretroviral regimen options to consider.~5. No documented detectable viral loads (HIV-1 RNA \<50 copies/ml) within the last 12 months prior to Screening Visit~6. Nadir CD4 cell count of \>200 cells/mm3~Exclusion Criteria:~1. CXCR4-tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ DNA Assay at the Screening Visit~2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg)~3. Any acquired immune deficiency syndrome (AIDS)-defining illness according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition~4. Prior use of any entry, attachment, CCR5 co-receptor, or fusion inhibitor, including PRO 140.~5. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRO 140 (Type: EXPERIMENTAL): PRO 140 350mg weekly SQ injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants prescribed perampanel for the adjunctive treatment of partial onset seizures based on independent clinical judgment of treating physicians.~Exclusion Criteria:~* Participation in another study involving administration of an investigational drug or device whilst participating in this observational study.~* Hypersensitivity \[allergic\] to perampanel.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: None): Participants receiving perampanel tablets, orally according to prescribing information and the treating physician's clinical judgment will be observed prospectively for up to 6 months or participant withdrawal, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior history of relapsing remitting MS~* SPMS defined as progressive increase of disability over at least 6 months~* EDSS score of 3.0 to 6.5~* No relapse of corticosteroid treatment within 3 months~Exclusion Criteria:~* Women of child bearing potential must use reliable forms of contraception.~* Diagnosis of Macular edema during screening period~* Any medically unstable condition determined by investigator.~* Unable to undergo MRI scans~* Hypersensitivity to any study drugs or drugs of similar class

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Siponimod (BAF312) (Type: EXPERIMENTAL): Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on the treatment epoch for 3 months. During the Core Part of the study, participants participated in a maximum of 3 epochs. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to BAF312 was administered orally during the Core Part of the trial. Following the Core Part, eligible participants enter the Extension Part during which all receive open-label BAF312.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Effectiveness RCT of Optimized Cessation Treatments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \>=18 years~* smoking \>4 cigarettes/day for the previous 6 months~* able to read, write, and speak English~* have reliable phone access and agree to respond to Interactive Voice Response (IVR) phone prompts~* and if currently using NRT, agreeing to use only study medication for the duration of the study~* we will not exclude participants based on their prior use of cessation medication or if they use multiple tobacco products in order to enhance real-world generalization (these will be statistically controlled in analyses)~* not currently attempting to quit smoking~* not intending to quit smoking (defined as no plans to quit in the next month)~* and planning to remain in the intervention catchment area for at least 12 months.~Exclusion Criteria:~* currently taking bupropion or varenicline~* medical contraindications to using NRT including hospitalized (for at least one night) for a stroke, heart attack, congestive heart failure or diabetes in the last 30 days~* diagnosis of or treatment for schizophrenia, a psychotic disorder or bipolar disorder in the last 10 years~* and, if the participant is a woman of childbearing potential, being pregnant or intending to becoming pregnant or unwillingness to use an approved method of birth control during treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Modern Usual Care (Type: ACTIVE_COMPARATOR): Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
- Abstinence-Optimized Cessation Treatment (Type: EXPERIMENTAL): There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 years or older~* Diagnosis of CF based on the following: sweat chloride\>60 mEq/L or genotype with 2 identifiable mutations consistent with CF; and one or more clinical features consistent with CF.~* Chronically infected with a Burkholderia cepacia complex species (\>50% of respiratory specimens positive in the 24 months prior to screening).~* Able to produce sputum (expectorated or induced).~* Able to reproducibly perform pulmonary function testing.~* Written informed consent provided.~Exclusion Criteria:~* Post lung transplantation.~* Pregnancy.~* Acute exacerbation requiring IV or oral antibiotics within 14 days~* Patients currently receiving inhaled tobramycin/TOBI~* A septic or clinically unstable patient, as determined by the investigator.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TOBI Podhaler (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete